Japan’s Shionogi is seeking approval for oral COVID-19 drug
Passengers wearing protective face masks are seen inside a train, in the middle of the coronavirus (COVID-19) pandemic, in Tokyo, Japan on February 9, 2022. REUTERS / Issei Kato
Sign up now for FREE unlimited access to Reuters.com
Sign up
TOKYO, February 25 (Reuters) – Drugmaker Shionogi & Co Ltd (4507.T) has applied for approval to make and sell its oral COVID-19 treatment in Japan, the company said Friday.
Known as S-217622, the drug will be the country’s third antiviral pill approved for coronavirus patients, after those developed by Pfizer Inc. (PFE.N) and Merck & Co (MRK.N). Read more
Sign up now for FREE unlimited access to Reuters.com
Sign up
Reporting by Rocky Swift; Editing Clarence Fernandez
Our standards: Thomson Reuters trust principles.